Maplight Therapeutics (NASDAQ:MPLT) CFO Vishwas Setia Sells 10,564 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CFO Vishwas Setia sold 10,564 shares of Maplight Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $28.24, for a total transaction of $298,327.36. Following the sale, the chief financial officer directly owned 356,256 shares of the company’s stock, valued at $10,060,669.44. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Tuesday, May 5th, Vishwas Setia sold 10,903 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total transaction of $307,464.60.
• On Monday, May 4th, Vishwas Setia sold 14,904 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.11, for a total transaction of $418,951.44.

Maplight Therapeutics Stock Up 4.0%

Shares of MPLT stock opened at $29.04 on Thursday. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $33.28. The firm has a market cap of $1.24 billion and a price-to-earnings ratio of -0.73. The company has a fifty day moving average price of $22.60.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($1.42). Sell-side analysts predict that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Needham & Company LLC initiated coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. HC Wainwright initiated coverage on shares of Maplight Therapeutics in a research note on Monday. They issued a “buy” rating and a $45.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Finally, TD Cowen initiated coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics News Summary

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: HC Wainwright opened/updated coverage and issued detailed quarterly and FY estimates alongside a Buy rating and a $45 price target (implies ~55% upside from the recent price); the report provides a near‑term analyst catalyst and a bullish valuation anchor. HC Wainwright coverage (MarketBeat)
• Positive Sentiment: Needham reaffirmed its Buy rating on MPLT, reinforcing sell‑side support that can sustain buying interest. Needham reaffirmation (The Globe and Mail)
• Neutral Sentiment: Morningstar quote/coverage appears in the tape (useful for tracking consensus/third‑party data) but contains no new fundamental update by itself. Morningstar MPLT quote
• Negative Sentiment: Significant insider selling reported May 4–6: CEO Christopher Kroeger sold multiple blocks (~23,701 shares on May 6 and earlier sales), CFO Vishwas Setia, and insiders James W. Lillie and Erin P. Foff also sold material stakes. These transactions reduce insider holdings and may add near‑term supply pressure, though each sale was made under pre‑arranged Rule 10b5‑1 plans (which weakens the signal that sales reflect new negative company information). See CEO Form 4 filing. CEO Form 4 (SEC)
• Negative Sentiment: Additional insider Form 4 filings for James W. Lillie and Erin P. Foff confirm multi‑day sales at similar prices (May 4–6). Investors should monitor total sold vs. remaining insider ownership and trading volume to gauge impact. James W. Lillie Form 4 (SEC)

Hedge Funds Weigh In On Maplight Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its stake in Maplight Therapeutics by 10.1% in the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock worth $802,000 after purchasing an additional 3,608 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics in the 4th quarter worth $49,168,000. Invesco Ltd. acquired a new position in Maplight Therapeutics in the 4th quarter worth $228,000. Vestal Point Capital LP acquired a new position in Maplight Therapeutics in the 4th quarter worth $6,763,000. Finally, Tudor Investment Corp ET AL acquired a new position in Maplight Therapeutics in the 4th quarter worth $840,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.